| Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial RJ Motzer, B Escudier, S Oudard, TE Hutson, C Porta, S Bracarda, ... The Lancet 372 (9637), 449-456, 2008 | 3723 | 2008 |
| Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised … B Burtness, KJ Harrington, R Greil, D Soulières, M Tahara, G de Castro, ... The Lancet 394 (10212), 1915-1928, 2019 | 2361 | 2019 |
| Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up B Escudier, C Porta, M Schmidinger, N Rioux-Leclercq, A Bex, V Khoo, ... Annals of Oncology 30 (5), 706-720, 2019 | 1599 | 2019 |
| Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors RJ Motzer, B Escudier, S Oudard, TE Hutson, C Porta, S Bracarda, ... Cancer 116 (18), 4256-4265, 2010 | 1516 | 2010 |
| Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study EEW Cohen, D Soulières, C Le Tourneau, J Dinis, L Licitra, MJ Ahn, ... The Lancet 393 (10167), 156-167, 2019 | 1379 | 2019 |
| Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma R Motzer, B Alekseev, SY Rha, C Porta, M Eto, T Powles, V Grünwald, ... New England Journal of Medicine 384 (14), 1289-1300, 2021 | 1270 | 2021 |
| Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma DF McDermott, MA Huseni, MB Atkins, RJ Motzer, BI Rini, B Escudier, ... Nature medicine 24 (6), 749-757, 2018 | 1048 | 2018 |
| Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised … RJ Motzer, BI Rini, DF McDermott, OA Frontera, HJ Hammers, ... The Lancet Oncology 20 (10), 1370-1385, 2019 | 725 | 2019 |
| Developing inhibitors of the epidermal growth factor receptor for cancer treatment V Grunwald, M Hidalgo Journal of the National Cancer Institute 95 (12), 851-867, 2003 | 660 | 2003 |
| Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy TK Eigentler, JC Hassel, C Berking, J Aberle, O Bachmann, V Grünwald, ... Cancer treatment reviews 45, 7-18, 2016 | 445 | 2016 |
| Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related … KJ Harrington, RL Ferris, G Blumenschein, AD Colevas, J Fayette, ... The Lancet Oncology 18 (8), 1104-1115, 2017 | 404 | 2017 |
| An update on the management of sporadic desmoid-type fibromatosis: a European consensus initiative between sarcoma PAtients EuroNet (SPAEN) and European organization for … B Kasper, C Baumgarten, J Garcia, S Bonvalot, R Haas, F Haller, ... Annals of Oncology 28 (10), 2399-2408, 2017 | 395 | 2017 |
| Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells V Grunwald, L DeGraffenried, D Russel, WE Friedrichs, RB Ray, ... Cancer research 62 (21), 6141-6145, 2002 | 365 | 2002 |
| Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): evaluation and management of adverse drug reactions JC Hassel, L Heinzerling, J Aberle, O Bähr, TK Eigentler, MO Grimm, ... Cancer treatment reviews 57, 36-49, 2017 | 318 | 2017 |
| Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial RJ Motzer, C Porta, NJ Vogelzang, CN Sternberg, C Szczylik, J Zolnierek, ... The Lancet Oncology 15 (3), 286-296, 2014 | 294 | 2014 |
| Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial BI Rini, B Melichar, T Ueda, V Grünwald, MN Fishman, JA Arranz, AH Bair, ... The lancet oncology 14 (12), 1233-1242, 2013 | 258 | 2013 |
| Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial D Cella, V Grünwald, B Escudier, HJ Hammers, S George, P Nathan, ... The Lancet Oncology 20 (2), 297-310, 2019 | 254 | 2019 |
| Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway LA DeGraffenried, L Fulcher, WE Friedrichs, V Grünwald, RB Ray, ... Annals of oncology 15 (10), 1510-1516, 2004 | 246 | 2004 |
| Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations SK Pal, JE Rosenberg, JH Hoffman-Censits, R Berger, DI Quinn, ... Cancer discovery 8 (7), 812-821, 2018 | 244 | 2018 |
| Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes P Schöffski, IL Ray-Coquard, A Cioffi, NB Bui, S Bauer, JT Hartmann, ... The lancet oncology 12 (11), 1045-1052, 2011 | 244 | 2011 |
